PDL BioPharma just filed its annual proxy statement, which details the salary information of its key executives. In 2015, the company's CEO made 3,866,135.

The table is included below:

< td width="1%">
Name and Title
Year
Salary
Bonus
Stock
Awards (1)
Non-Equity
Incentive Plan
Compensation
All Other
Compensation
Total
John P. McLaughlin
2015
$
737,591

$

$
984,510

$
2,134,034

(2)
$
10,000

(3)
$
3,866,135

President and Chief
2014
$
716,108

$

$
984,510

$
2,359,424

$
10,000

$
4,070,042

Executive Officer
2013
$
695,250

$
469,000

$
201,000

$
1,511,875

$
10,000

$
2,887,125

Christopher Stone
2015
$
428,233

$

$
327,990

$
709,987

(4)
$
10,000

(5)
$
1,476,210

Vice President, General
2014
$
415,760

$

$
252,300

$
1,059,315

$
10,000

$
1,737,375

Counsel and Secretary
2013
$
401,700

$
258,000

$
110,600

$
559,275

$
10,000

$
1,339,575

Peter Garcia
2015
$
417,768

$

$
325,384

$
694,933

(6)
$
58,000

(7)
$
1,496,085

Vice President and Chief
2014
$
405,600

$

$
250,295

$
1,000,668

$
58,000

$
1,714,563

Financial Officer
2013
$
248,182

(8)
$

(9)
$
105,000

$
239,850

(10)
$
40,581

$
633,613

Danny Hart
2015
$
370,800

$

$
304,500

$
611,938

(12)
$
40,000

(13)
$
1,327,238

Vice President,
2014
$
343,075

(11)
$

$
217,500

$
776,550

$
40,000

$
1,377,125

Business Development
2013
$
286,888

(14)
$
222,710

(15)
$
97,390

(16)
$
306,310

$
40,000

$
953,298

Steffen Pietzke
2015
$
134,924

$

$
100,256

$
87,750

(17)
$
37,754

(18)
$
360,684

Controller and Chief
Accounting Officer
David Montez
2015
$
116,070

(19)
$

$
18,489

$

$
379,642

(20)
$
514,201

Former Controller and
2014
$
249,600

$

$
91,140

$
299,933

(21)
$
28,000

(22)
$
668,673

Chief Accounting Officer
2013
$
105,000

(23)
$

(9)
$
30,200

$
57,942

(10)
$
14,720

$
207,862

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever PDL BioPharma makes a similar move, sign up!

Other recent filings from the company include the following:

Current report, items 7.01 and 9.01 - Nov. 14, 2017
PDL BioPharma Just Filed Its Quarterly Report: 2. Net Income per Sh... - Nov. 13, 2017
Notification of inability to timely file Form 10-Q or 10-QSB - Nov. 13, 2017
Pdl Biopharma’S Proposal To Acquire Neos Therapeutics Expires Today; - Nov. 8, 2017
PDL: Cook Williams Communications, Inc - Nov. 2, 2017

Auto Refresh

Feedback